Parallel biobanking of post-COVID-19 cancer patient samples as an innovative route to multiomics screening

Compared to the concept of biobanks, which include one type of biomaterials from patients or a library of DNA samples, new types of biobanks shouldn’t be only repositories, but also infrastructure, which allows for innovative and translational research using biomaterials from patients. Also, parallel biobanking, including the simultaneous collection of various types of biomaterials (whole blood, plasma, exosomes, DNA, microRNA, leukocytes, tumor cells and their microenvironment — frozen with preservation of their viability, etc.) will allow them to be used in in-vitro models to test the effects of drugs, as well as to predict the development of treatment-resistant populations of cancer cells and cellular transformation. This biobanking approach opens new opportunities to study precancerous niches, rare forms of cancer and to develop personalized therapeutic strategies, giving researchers new opportunities for in vitro recapitulation of tissue mechanical and molecular changes, changes of signaling molecules profile and secretome. Keywords: biobank, biocollection, head and neck cancer, malignant tumors, translational medicine, personalized medicine, oncology, extracellular matrix Conflicts of interest. The authors have no conflicts of interest to declare. Funding. Supported by Grant No. 21-15-00411 of the Russian Science Foundation and Agreement No. 141-032024-014 (122030900062-5).